1677-25-4

Basic information

• Product Name: Benzoyl chloride, 2-Mercapto-
• Synonyms: Benzoyl chloride, 2-Mercapto-;2-Mercaptobenzoyl chloride
• CAS NO: 1677-25-4
• Molecular Formula: C₇H₅ClOS
• Molecular Weight: 172.632
• Mol File: 1677-25-4.mol
• Article Data: 5

Chemical Properties

• Melting Point: 46-48 °C
• Boiling Point: 262.7±23.0 °C(Predicted)
• Appearance: /
• Density: 1.343±0.06 g/cm3(Predicted)
• PKA: 5.60±0.43(Predicted)
• CAS DataBase Reference: Benzoyl chloride, 2-Mercapto-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoyl chloride, 2-Mercapto-(1677-25-4)
• EPA Substance Registry System: Benzoyl chloride, 2-Mercapto-(1677-25-4)

Safety Data

• Hazardous Substances Data: 1677-25-4(Hazardous Substances Data)

Upstream product

• 118-92-3 anthranilic acid 
• 147-93-3 Thiosalicylic acid 

Downstream Products

• 24611-43-6 2-mercaptobenzoic acid hydrazide 
• 66591-55-7 2-mercapto-benzoic acid-[3-(2r,6c-dimethyl-piperidino)-propylester]; hydrochloride 
• 67032-17-1 2-mercapto-benzoic acid-[3-(2-methyl-piperidino)-propylester]; hydrochloride 
• 1144043-04-8 (2-mercapto-phenyl)-morpholin-4-yl-methanone 
• 49755-51-3 2-mercapto-N,N-diethyl-benzamide 
• 75406-31-4 benzyl 2-mercaptobenzoate 

Relevant articles and documents

Compound for preparing baloxavir or derivatives thereof as well as preparation method and application of compound

The invention relates to a preparation method of a compound shown as a formula VIII for preparing baloxavir or derivatives thereof, a compound shown as a formula I for preparing the compound shown asthe formula VIII and a preparation method of the compound shown as the formula I. The compound shown as the formula I is used for preparing the compound shown as the formula VIII, the baloxavir or thederivative thereof. The preparation method is simple and convenient to operate, and the raw materials are easily available and low in cost; reaction conditions are mild, and the method is safe and environment-friendly; side reactions are few, and the product purity is high; and the quality is controllable, and the method is suitable for industrial production.

Scaffold Diversity Inspired by the Natural Product Evodiamine: Discovery of Highly Potent and Multitargeting Antitumor Agents

A critical question in natural product-based drug discovery is how to translate the product into drug-like molecules with optimal pharmacological properties. The generation of natural product-inspired scaffold diversity is an effective but challenging strategy to investigate the broader chemical space and identify promising drug leads. Extending our efforts to the natural product evodiamine, a diverse library containing 11 evodiamine-inspired novel scaffolds and their derivatives were designed and synthesized. Most of them showed good to excellent antitumor activity against various human cancer cell lines. In particular, 3-chloro-10-hydroxyl thio-evodiamine (66c) showed excellent in vitro and in vivo antitumor efficacy with good tolerability and low toxicity. Antitumor mechanism and target profiling studies indicate that compound 66c is the first-in-class triple topoisomerase I/topoisomerase II/tubulin inhibitor. Overall, this study provided an effective strategy for natural product-based drug discovery. (Figure Presented).

TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. More precisely, the present invention relates to tricyclic derivatives as colchicine derivatives, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. Tricyclic derivatives of the present invention show very powerful cytotoxicity to cancer cell lines but were much less toxic than colchicine or taxol, confirmed through animal toxicity test. Tricyclic derivatives of the invention also decrease the volume and weight of a tumor and have a strong angiogenesis inhibiting activity in HUVEC cells. Thus, tricyclic derivatives of the present invention can effectively be used as an anticancer agent, anti-proliferation agent and an angiogenesis inhibitor.